Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults

201378 citationsJournal Articlebronze Open Access

Authors

Kathleen M. Mullane · University of Chicago Medical Center

Drew J. Winston · University of California, Los Angeles

M. S. Wertheim · Hematology Oncology Associates

Robert F. Betts · University of Rochester Medical Center

Donald M. Poretz · Clinical Alliance for Research and Education-Infectious Diseases

Luis H. Camacho · Hematology Oncology Consultants

Steven A. Pergam

Abstract

ZVHT was generally safe and immunogenic through 28 days post-dose 4 in adults with STM, HM, and HIV. Autologous-HCT but not allogeneic-HCT patients had a rise in T-cell response; antibody responses were not increased in either HCT population. Study identification. V212-002 Clinical Trials Registration. NCT00535236.

Topics & Keywords

Herpesvirus Infections and Treatments Poxvirus research and outbreaks Drug-Induced Adverse Reactions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Infectious Diseases

Volume 208, Issue 9, pp. 1375-1385

DOI: 10.1093/infdis/jit344

Field-Weighted Citation Impact: 5.58